Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/80193
Title: Edging closer towards the goal of a dengue vaccine
Authors: Wilder-Smith, Annelies
Yoon, In-Kyu
Keywords: Efficacy
Non-structural proteins
Risk-benefit ratio
Dengue vaccines
CYD-TDV
Issue Date: 2016
Source: Wilder-Smith, A., & Yoon, I.-K. (2016). Edging closer towards the goal of a dengue vaccine. Expert Review of Vaccines, 15(4), 433-435.
Series/Report no.: Expert Review of Vaccines
Abstract: Dengue is a growing global problem that urgently needs to be addressed [1]. Similarly to yellow fever, dengue is caused by viruses of the flaviviridae family and transmitted by Aedes mosquitoes, but unlike yellow fever for which we have had a vaccine for more than 80 years, the first dengue vaccine is only available now. Research and Development funding for dengue vaccine development has more than tripled in the past decades, much of which is driven by vaccine manufacturers [2]. We have a robust pipeline with several promising dengue vaccine candidates, all using different approaches [3]. The only vaccine to have completed Phase 3 trials is the CYD-TDV (a live attenuated recombinant chimeric tetravalent dengue vaccine developed by Sanofi Pasteur) sponsored by Sanofi Pasteur. Interestingly, the relatedness to other flaviviruses played a role in the development of CYD-TDV in which the 17D yellow fever virus backbone is used for chimerization with dengue viruses (DENVs). CYD-TDV is a formulation of four chimeras, each one engineered to express the envelope and pre-membrane proteins from one of the four serotypes of DENV [4]. Dengvaxia (CYD-TDV) was first licensed in Mexico in December 2015, and is meanwhile licensed in three other countries.
URI: https://hdl.handle.net/10356/80193
http://hdl.handle.net/10220/40434
ISSN: 1476-0584
DOI: 10.1586/14760584.2016.1154459
Schools: Lee Kong Chian School of Medicine (LKCMedicine) 
Rights: © 2016 Taylor & Francis. This is the author created version of a work that has been peer reviewed and accepted for publication by Expert Review of Vaccines, Taylor & Francis. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [http://dx.doi.org/10.1586/14760584.2016.1154459].
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles

Files in This Item:
File Description SizeFormat 
Edging closer towards the goal of a dengue vaccine.pdfMain article445.52 kBAdobe PDFThumbnail
View/Open

SCOPUSTM   
Citations 20

11
Updated on Apr 20, 2024

Web of ScienceTM
Citations 20

9
Updated on Oct 27, 2023

Page view(s) 20

620
Updated on Apr 13, 2024

Download(s) 50

165
Updated on Apr 13, 2024

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.